Medicus Pharma Ltd.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
MDCX$1.87+2.2%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three months ended March 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss for the period | $(5,102,408) | $(1,707,358) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation expense | 112,277 | 35,953 | ||
| Change in operating lease right-of-use assets | 23,480 | 30,945 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses | 122,639 | 61,643 | ||
| Accounts payable | 655,634 | 364,275 | ||
| Accrued expenses and other current liabilities | 299,203 | (9,657) | ||
| Operating lease liability | (27,575) | - | ||
| Related party payable | (24,244) | 47,266 | ||
| Net cash used in operating activities | (3,940,994) | (1,176,933) | ||
| Cash flows from financing activities: | ||||
| Net proceeds from issuance of common shares and warrants in connection with Regulation A | 3,784,101 | - | ||
| Cash paid for financing costs in connection with SEPA | (25,000) | - | ||
| Net cash provided by financing activities | 3,759,101 | - | ||
| Net decrease in cash and cash equivalents during the period | (181,893) | (1,176,933) | ||
| Cash and cash equivalents, beginning of the year | 4,164,323 | 1,719,338 | ||
| Cash and cash equivalents, end of the year | $3,982,430 | $542,405 | ||
| Supplemental disclosure of non-cash investing and financing activities | ||||
| Right-of-use assets obtained in exchange for lease liabilities | $ | - | $356,805 | |
| Receivable for proceeds of warrant exercises | $14,000 | $ | - | |
| Issuance costs included in accounts payable | $95,120 | $ | - | |
| Deferred issuance costs on issued shares related to SEPA agreement | $300,000 | $ | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.